Stocktwits on MSN
UNCY stock clocks worst day in a year — analysts keep buy ratings despite ‘5-12 month delay’ in drug approval
The company was seeking approval for the drug to treat hyperphosphatemia in patients with chronic kidney disease on dialysis. ・Both B. Riley and H.C. Wainwright kept their ‘Buy’ ratings on the stock ...
Unicyive Therapeutics is awaiting word on whether its main drug, oxylanthanum carbonate, will be approved to treat ...
Asianet Newsable on MSN
UNCY stock rallies 8% as retail traders anticipate FDA clearance for lead drug candidate
Unicyive is awaiting word on whether its main drug, oxylanthanum carbonate, will be approved to treat hyperphosphatemia in ...
In late June 2026, Unicycive Therapeutics received a Complete Response Letter from the FDA on its resubmitted oxylanthanum carbonate NDA, citing unresolved third-party manufacturing deficiencies while ...
Unicycive Therapeutics ( (UNCY)) just unveiled an announcement. On November 14, 2025, Unicycive Therapeutics, Inc. amended its sales agreement with Guggenheim Securities, LLC to increase the potential ...
Detailed price information for Unicycive Therapeutics Inc (UNCY-Q) from The Globe and Mail including charting and trades.
Unicycive Therapeutics Inc. Annual stock financials by MarketWatch. View the latest UNCY financial statements, income statements and financial ratios.
Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to indicate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results